Supplementary Materials

The PDF file includes:

  • Materials and Methods
  • Fig. S1. Increased KDM5A improves the efficacy of anti–PD-1 blockade immunotherapy.
  • Fig. S2. Blocking PI3K-AKT-S6K signaling decreases PD-L1 abundance in MC38 cells.
  • Fig. S3. Development of a small molecule that increases KDM5A abundance for use in combination immunotherapy.
  • Fig. S4. The presence of KDM5A and PD-L1 on CD45 cells in MC38 tumors.
  • Fig. S5. Combination therapy with D18 and anti–PD-1 antibody promotes activation of cytotoxic CD8+ T cells.
  • Fig. S6. Combination therapy with D18 and anti–PD-1 antibody promotes activation of TH1 CD4+ T cells and increases central memory cells in the spleen.
  • Fig. S7. Combination therapy with D18 and anti–PD-1 antibody increases tumor-infiltrating CD103+ DCs and M1 macrophages.
  • Fig. S8. Schematic for the mechanisms by which D18 improves responses to anti–PD-1/anti–PD-L1 antibody.
  • Table S1. DNA oligo sequences used in this study.
  • Legends for data files S1 to S3
  • References (7077)

[Download PDF]

Other Supplementary Material for this manuscript includes the following:

  • Data file S1 (Microsoft Excel format). The differentially expressed genes and top 20 gene signatures in LMCs.
  • Data file S2 (Microsoft Excel format). Genes in the KDM5A gene signature and other published biomarker sets.
  • Data file S3 (Microsoft Excel format). Original data.